Clinicians use anti-epidermal growth factor receptor (EGFR) therapy and immune checkpoint inhibitors along with traditional cytotoxic chemotherapy in patients with recurrent or metastatic cancer [2]. Here, EGFR is linked to metastatic malignant neoplasm.